Press releases

Release issued 4th September 2006

London, UK, 4 September 2006 - Cancer Research Technology (CRT), the oncology-focused development and commercialisation company wholly owned by Cancer Research UK, today announce that they have entered into an agreement with AstraZeneca focused on colorectal cancer.

Within the agreement, the Cancer and Immunogenetics Laboratory led by Sir Walter Bodmer at the Weatherall Institute of Molecular Medicine will collaborate with AstraZeneca to characterise the expression of key genes involved in colorectal cancer. The Cancer and Immunogenetics laboratory will provide critical reagents and data and the programme of research will be undertaken by AstraZeneca. The findings of this collaboration will be shared by both CRT and AstraZeneca.

The data generated will be used to advance AstraZeneca's proprietary anti-colorectal cancer programs by increasing the understanding of the link between molecular pathology of disease and efficacy of novel targeted therapeutics aimed at colorectal cancer. The results will assist in the identification of novel drug targets and in development of drugs that are effective against chemoresistant tumours.

According to Sir Walter Bodmer, "We are very excited by the opportunities offered by this collaboration between our laboratory in Oxford, CRT and AstraZeneca. The information collected will greatly enhance our ability to relate and target drug responses to the molecular pathology of colorectal cancers."

Dr. Les Hughes, Head of Cancer and Infection Research at AstraZeneca, adds, "This is a promising collaboration which builds on the strengths of both institutions. By combining our expertise I am confident that this partnership will result in findings which will ultimately benefit cancer patients."

Colorectal cancer is the fourth most common cause of death from cancer worldwide. Each year an estimated one million people are diagnosed with colorectal cancer, accounting for 8% of deaths from cancer. Current treatments for advanced disease are primarily palliative and the 5-year survival rate for patients with advanced colorectal cancer is less than 10%.

---ends---

For further information:

Cancer Research Technology Limited Nick Wells, Head of Marketing +44 207 269 3640

nwells@cancertechnology.com

About AstraZeneca

AstraZeneca is a major international healthcare business engaged in the research, development, manufacture and marketing of prescription pharmaceuticals and the supply of healthcare services. It is one of the world's leading pharmaceutical companies with healthcare sales of $23.95 billion and leading positions in sales of gastrointestinal, cardiovascular, neuroscience, respiratory, oncology and infection products. AstraZeneca is listed in the Dow Jones Sustainability Index (Global) as well as the FTSE4Good Index.

About Cancer Research Technology Limited

Cancer Research Technology Limited (CRT) is an oncology-focused development and commercialisation company that realises cancer patient benefit from publicly- funded research worldwide. CRT works closely with leading international cancer scientists, their institutes and funding bodies to protect, develop and commercialise oncology-related discoveries. CRT is wholly owned by Cancer Research UK, the largest independent funder of cancer research in the world. Further information about CRT can be found at www.cancertechnology.com.

About Cancer Research UK Cancer Research UK is Europe's leading cancer charity, dedicated to research into the causes, prevention and treatment of cancer. The charity supports the work of 3,000 scientists, doctors and nurses in over 80 academic centres across the UK, with an annual scientific spend of more than £217 million. Cancer Research UK is the European leader in the development of novel anti-cancer treatments; from their discovery at the laboratory bench to early clinical trials in cancer patients. Further information about Cancer Research UK can be found at www.cancerresearchuk.org.

(28th August 2007) CRT Begins Critical Role in New Australian Cancer Research Venture

(21st August 2007) CRT Establishes Crystallography Facility at Birkbeck, University of London

(17th July 2007) CRT and The Beatson Institute Announce Research Collaboration in Tumour Imaging with AstraZeneca

(11th July 2007) Abiogen Licenses RFB4 Antibody from Cancer Research Technology

(22nd June 2007) Cambridge Scientist Wins Innovation Award for Cancer Diagnostic Markers